Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Upper Limb Cardiopulmonary Exercise Test in Friedrich Ataxia Patients
Movement Disorders
P8 - Poster Session 8 (8:00 AM-9:00 AM)
3-001
To explore the feasibility of upper limbs cardiopulmonary exercise test (CPX) in Friedreich Ataxia (FRDA) patients and to compare the results with a sex, age and Body Mass Index (BMI) matched cohort of Healthy Controls (HC).
FRDA is an autosomal recessive disease with no available therapy. Apart form clinical scales and biochemical endpoints, functional measures for clinical trials are currently missing.

CPX was performed using an upper limbs cycle ergometer (Ergoline GmbH, Blitz, Germany). Respiratory gas exchange measurements were obtained breath by breath (Sensormedics, Yorba Linda, CA, USA). Peak oxygen uptake (VO2max) was recorded at the mean value of VOduring the last 20 sec of the test. The ventilatory anaerobic threshold was detected by the use of the V-slope method. Continuous variables were compared between groups using an unpaired t test, categorical variable were compared using a chi-square test. Correlation was performed using the Parson’s correlation coefficient. 

We studied 54 FRDA patients and 22 HC. Age (35.3±13.8 vs 33.4±9.9;p=0.559), gender (M:F 28:27 vs 8:14;p=0.248), and BMI (23.1±4.6 vs 23.0±3.4;p=0.928) did not differ between groups. VO2max (13.95±4.7 vs 25.68±5.9 mL/Kg/min;p<0.001), peak workload (43.87±12.0 vs 76.18±20.0 watts;p<0.001), and test duration (4.29±2.4 vs 10.93±2.5 min;p<0.001) were reduced in FRDA patients. Sixty-four percent of patients, and 32% of HC reached the anaerobic threshold (p=0.011). VE/VCOslope was higher in FRDA compared to HC (32.87±5.1 vs 28.48±5.9;p=0.002). In FRDA patients, VO2max inversely correlated with BMI (R=-0.333;p=0.014), interventricular septum thickness (R= -0.281;p=0.039), SARA  (R= -0.434;p=0.001), disease duration (R= -0.397;p=0.003), and 9HPT performance (R= -0.437;p=0.001). VO2max directly correlated with ADL (R=0.536;p<0.001), and IADL (R=0.385;p=0.004).

FRDA patients showed half of HC’s oxygen consumption with reduced maximum effort, and reached the anaerobic threshold two times more frequently than HC. This indicates that FRDA have a reduced aerobic metabolism that parallels reduced physical performance, and that reflects disease severity.
Authors/Disclosures
Francesco Sacca, MD, FÂé¶¹´«Ã½Ó³»­ (University Federico II)
PRESENTER
Dr. Sacca has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Sacca has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lexeo. Dr. Sacca has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genpharm. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medpharma. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Madison Pharma. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zai Lab. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dianthus. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Reata. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neopharm Israel. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Johnson&Johnson. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Sacca has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Astrazeneca. The institution of Dr. Sacca has received research support from AIFA. The institution of Dr. Sacca has received research support from FARA.
Chiara Pane, MD Dr. Pane has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Giuseppe De Michele, MD No disclosure on file
Alessandro Filla, MD, FÂé¶¹´«Ã½Ó³»­ No disclosure on file
No disclosure on file